Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 11
HOS-108840 · Präparat HOS-093083
Abacavir, Zidovudine Abacavir, Zidovudine: The clinical significance of Concentrations may be reduced reduced abacavir and zidovudine due to increased glucuronidation concentrations is unknown. by lopinavir/ritonavir. Tenofovir disoproxil Tenofovir: No dose adjustment necessary. fumarate (DF), 300 mg QD AUC: ↑ 32% Higher tenofovir concentrations Cmax: ↔ could potentiate tenofovir (equivalent to 245 mg Cmin: ↑ 51% associated adverse events, tenofovir disoproxil) including renal disorders. Lopinavir: ↔ Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage AUC: ↓ 20% recommendation or consider Cmax: ↓ 13% alternative therapy. Cmin: ↓ 42% Nevirapine, 200 mg BID Lopinavir: See section 4.2 for Kaletra dosage AUC: ↓ 27% recommendation or consider Cmax: ↓ 19% alternative therapy. Cmin: ↓ 51% Etravirine Etravirine: No dose adjustment necessary AUC: ↓ 35% (Lopinavir/ritonavir tablet Cmin: ↓ 45% 400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) zidovudine (HOS-085837) efavirenz (HOS-087947) nevirapine (HOS-088064) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 7e8d3e75ebcfb46fcb48f151d995ceb0e62959fafd1f9cc35b54c2dafa32e31e · Zeichen 2252–4083 im Abschnitt